Dr. Jianchun Duan 段建春
Chief Physician
Department of Oncology Rehabilitation, Shanxi Cancer Hospital, Taiyuan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Multidisciplinary and individualized treatment for thoracic tumors, especially lung cancer. Expertise in bronchoscopic diagnosis and treatment, chemotherapy, molecular targeted therapy, and biomarker-guided individualized therapy.
Dr. Duan holds a master’s degree from West China Medical Center (2004) and a PhD in Oncology from Peking University Health Science Center (2011). Promoted to Associate Chief Physician in 2012 and currently serves as Chief Physician. Dr. Duan has participated in over 10 multicenter clinical trials and received awards including the Ministry of Education Science and Technology Award (Second Class) and the Chinese Medical Award (Third Class).
Name order: in Chinese the family name comes first (Duan Jianchun). Papers usually list the name as Jianchun Duan or Duan J.
Selected publications
31 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2026 (senior author): Different genetic associations of chronic lung diseases and lung cancer risk in European and East Asian populations. PubMed 42619367
- Adv Ther, 2026 (first author): Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study. PubMed 42667570
- Cancer Cell, 2026 (first author): HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial. PubMed 41791381
- CA Cancer J Clin, 2026 (first author): Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. PubMed 41818162
- Innovation (Camb), 2026 (first author): Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study. PubMed 41737326
- Front Pharmacol, 2025 (senior author): Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches. PubMed 40520158
- BMC Cancer, 2024 (senior author): Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis. PubMed 39455981
- Thorac Cancer, 2024 (senior author): Screening for depression and anxiety in lung cancer patients: A real-world study using GAD-7 and HADS. PubMed 38523362
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion